Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UNLOCK TARLATAMAB in SCLC and NECs
NCT07016230Phase 2Recruiting
- Sponsor
- Gustave Roussy
- Start
- Jul 2025
- Primary completion
- May 2027
- Modality
- Bispecific Antibodies, T-cell Engagers
- Countries
- 1
01
Overview
Phase 2, open-label trial of tarlatamab in small cell lung cancer (SCLC) and neuroendocrine carcinoma (NEC) (2 cohorts), sponsored by Gustave Roussy. Primary endpoint: Objective Response Rate at 4 months. Started Jul 2025; status: recruiting.
02
Drugs
tarlatamab
03
Conditions
small cell lung cancer (SCLC)neuroendocrine carcinoma (NEC)
Beyond the preview
Go deeper on NCT07016230.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07016230.